Is IDEXX Laboratories profitable in 2026?

Yes. IDEXX reported FY2025 net income of approximately $1.06 billion on revenue of about $4.30 billion as of December 31, 2025, and guided FY2026 EPS of $14.29 to $14.80 with revenue of $4,632M to $4,720M as of February 2, 2026.

Could AI replace IDEXX Laboratories?

Unlikely soon. IDEXX is deploying its own AI tools, like inVue Dx and DecisionIQ, atop proprietary hardware installed in clinics, a 10 million plus pathologist-labeled image dataset, and long-term exclusive contracts covering about 80% of revenue, making its diagnostic workflow hard for outside AI entrants to replicate as of January 2024 launch data.

Who is IDEXX Laboratories' biggest competitor?

Antech Diagnostics, owned by Mars Veterinary Health and merged with Heska, is viewed as IDEXX's strongest reference-lab rival as of June 2026 commentary; Zoetis is investing heavily in diagnostics but still lacks comparable reference-lab infrastructure.

Who owns IDEXX Laboratories?

IDEXX Laboratories is a publicly traded company with no parent, incorporated in Delaware and listed on NASDAQ as IDXX since 1991. Market capitalization was approximately $44.5 billion with a share price around $543.83 as of July 24, 2026.

Is IDEXX Laboratories losing market share to Mars or Zoetis?

No visible share loss as of Q1 2026. IDEXX's CAG Diagnostics recurring revenue grew 11% year over year into Q1 2026 (ended March 31, 2026), even as Mars combined Antech with Heska and Zoetis expanded its diagnostics investment.

Why is IDEXX Laboratories facing an antitrust lawsuit?

The Yuen et al. v. IDEXX Laboratories class action, filed July 2022 in the Northern District of California, alleges IDEXX locks roughly 80% of its revenue into long-term exclusive veterinary practice contracts, echoing 2012-2013 FTC findings of over 70% point-of-care market share via exclusive distribution deals.

Biotech tools companies · United States

IDEXX Laboratories

idexx.com ↗

Vet diagnostics leader: lab instruments, reference labs, and clinic software.

Hard to displace

Assessed 24 July 2026 · Evidence as of 24 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 24 July 2026 · Checkable from August 4, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, first under new CEO Erickson

The call

IDEXX keeps growing through exclusive contracts and its own AI tools while Mars/Antech and Zoetis compete hard without visibly pulling clinics away.

IDEXX sells diagnostic machines, lab tests, and practice management software to veterinary clinics worldwide. The company is hard to replace because it has installed machines in tens of thousands of clinics, signed long-term contracts that lock in about 80% of its revenue, runs same-day lab results, and built software that clinics use daily. Rivals like Mars (which owns Antech and Banfield clinics) and Zoetis are investing heavily, but they have not yet taken meaningful market share from IDEXX. The biggest threat is not a competitor or new technology, but a lawsuit challenging whether IDEXX's exclusive contracts are unfair, which could take years to resolve and might force the company to renegotiate those deals.

Why

AI pressure: Zoetis AI-enabled diagnostic and imaging tools. Zoetis is building AI diagnostic tools, but IDEXX is folding AI into its own boxes (inVue Dx, DecisionIQ) inside clinics it already owns. Could AI do the core job? Unlikely.

Bigger players: Mars/Antech (post-Heska merger) and Zoetis. Antech now has Heska's boxes and Mars owns Banfield and VCA clinics, but IDEXX's recurring diagnostics still grew 11% in Q1 2026. Could a giant copy it? No, they are blocked.

What protects it. Long-term exclusive contracts lock roughly 80% of revenue, backed by same-day reference-lab logistics and VetConnect PLUS software clinics already run on.

What would change this call

Ruling or settlement in Yuen v. IDEXX (N.D. Cal.) on exclusive contract terms. Would show whether IDEXX's contract-based moat is legally vulnerable.
IDEXX inVue Dx placements vs ~5,500 unit 2026 target reported in quarterly filings. A material miss would signal slowing hardware lock-in and growth strain.
Antech (Mars) or Zoetis quarterly filings citing diagnostics or practice-management share gains from IDEXX clinics. Would show rivals actually converting IDEXX-locked clinics rather than just investing.

Key numbers

Q1 2026 revenue up 14.3% YoY to $1.14B (2026-03-31)
CAG diagnostics recurring revenue up 11% YoY (2026-03-31)
FY2026 revenue guidance $4.63B-$4.72B (2026-02-02)

Named risks

Yuen v. IDEXX antitrust class action alleging 80% of revenue locked in exclusive contracts, unresolved since July 2022. Severity: high
inVue Dx placement pace could miss the 5,500-unit 2026 target given premium 41-43x P/E valuation. Severity: medium
Softer US companion-animal clinic visit trends flagged as a headwind into Q2/Q3 2026. Severity: medium
CEO transition execution risk during May 2026 handover from Mazelsky to Erickson. Severity: low
State-level AI regulation (e.g., California, Colorado) could affect deployment pace of AI diagnostic tools per 2025 10-K. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Mars Veterinary Health (Antech, merged with Heska)	contesting	Mars combined Antech with Heska to strengthen reference-lab competition, still no share loss shown by Q1 2026.
Zoetis	contesting	Investing heavily in diagnostics as of 2026 commentary but lacks reference-lab infrastructure comparable to IDEXX.
Antech Diagnostics	contesting	Viewed by industry commentary in June 2026 as IDEXX's strongest reference-lab rival.

Questions people ask

Is IDEXX Laboratories profitable in 2026?: Yes. IDEXX reported FY2025 net income of approximately $1.06 billion on revenue of about $4.30 billion as of December 31, 2025, and guided FY2026 EPS of $14.29 to $14.80 with revenue of $4,632M to $4,720M as of February 2, 2026.
Could AI replace IDEXX Laboratories?: Unlikely soon. IDEXX is deploying its own AI tools, like inVue Dx and DecisionIQ, atop proprietary hardware installed in clinics, a 10 million plus pathologist-labeled image dataset, and long-term exclusive contracts covering about 80% of revenue, making its diagnostic workflow hard for outside AI entrants to replicate as of January 2024 launch data.
Who is IDEXX Laboratories' biggest competitor?: Antech Diagnostics, owned by Mars Veterinary Health and merged with Heska, is viewed as IDEXX's strongest reference-lab rival as of June 2026 commentary; Zoetis is investing heavily in diagnostics but still lacks comparable reference-lab infrastructure.
Who owns IDEXX Laboratories?: IDEXX Laboratories is a publicly traded company with no parent, incorporated in Delaware and listed on NASDAQ as IDXX since 1991. Market capitalization was approximately $44.5 billion with a share price around $543.83 as of July 24, 2026.
Is IDEXX Laboratories losing market share to Mars or Zoetis?: No visible share loss as of Q1 2026. IDEXX's CAG Diagnostics recurring revenue grew 11% year over year into Q1 2026 (ended March 31, 2026), even as Mars combined Antech with Heska and Zoetis expanded its diagnostics investment.
Why is IDEXX Laboratories facing an antitrust lawsuit?: The Yuen et al. v. IDEXX Laboratories class action, filed July 2022 in the Northern District of California, alleges IDEXX locks roughly 80% of its revenue into long-term exclusive veterinary practice contracts, echoing 2012-2013 FTC findings of over 70% point-of-care market share via exclusive distribution deals.

Timeline

2026-07-24Market cap approximately $44.5 billion, share price around $543.83.
2026-07-01IDEXX announces Q2 2026 earnings release scheduled for August 4, 2026.
2026-06-11Stifel conference report: inVue Dx placements at 1,100 in Q1 2026 against a 5,500-unit 2026 target.
2026-03-31Q1 2026 revenue rose 14.3% YoY to $1.14 billion; CAG Diagnostics recurring revenue grew 11%.
2026-02-02FY2025 results reported; Q4 revenue grew 14% reported, 12% organic; FY2026 guidance issued.
2026-01-14IDEXX Cancer Dx panel reported in use by over 5,500 US and Canada practices.
2026-01-13CEO succession announced: Mazelsky to Executive Chair, Erickson to CEO effective May 12, 2026.
2026-01ImageVue DR50 Plus AI-powered digital radiography launched in North America.
2025-04-02Texas appeals court affirms judgment against IDEXX of about $19M royalties plus $30M interest.
2025-03IDEXX Cancer Dx panel launched for canine lymphoma.

Revision history

24 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Merck KGaA (MilliporeSigma)Intertek Group plc Eurofins Scientific SE